GlassScriptPhysician profile
Bac Nguyen
NPI 1295700326
$17,134.27
in general payments reported to CMS, 2019-2025
62 companies · $2,625 in 2025
The $2,625 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,293 · 2020: $1,894 · 2021: $2,514 · 2022: $2,299 · 2023: $2,463 · 2024: $3,047 · 2025: $2,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,116 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,115.78 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,542.23 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,906.64 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,481.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,429.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,290.68 | 2019-2025 | |
| Lilly USA, LLC | $1,138.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $994.09 | 2019-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $652.75 | 2023-2025 | |
| Astellas Pharma US INC | $574.17 | 2019-2025 | Veozah |
| Abbott Laboratories | $395.69 | 2019-2025 | Freestyle Libre 3, Infinity |
| Daiichi Sankyo INC. | $367.10 | 2020-2025 | Injectafer |
| Kowa Pharmaceuticals America, INC. | $345.81 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.43 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Allergan, INC. | $271.68 | 2020 | |
| Exact Sciences Corporation | $270.05 | 2023-2025 | Cologuard Collection Kit |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bac Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.